Zylox-Tonbridge Medical Technology Co., Ltd. engages in the production and sales of neurovascular and peripheral-vascular interventional surgical devices. The company is headquartered in Hangzhou, Zhejiang and currently employs 875 full-time employees. The company went IPO on 2021-07-05. The neurovascular interventional devices primarily include SilverSnake Intracranial Support Catheter, Phoenix Neurovascular Embolization Coil, Tonbridge Kylin Flow Diverter, Thrombite Clot Retriever Device and Beidou SS Neurovascular Guidewire. The peripheral vascular interventional devices primarily include UltraFree Drug Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, ZYLOX Octoplus Retrievable Inferior Vena Cava Filter, Snare Retrieval Kit for Inferior Vena Cava Filter and ZYLOX Swan Endovenous Radiofrequency Ablation Catheter. The firm primarily operates its businesses in the domestic market and overseas markets, including Germany, France, Italy, and Turkiye.
02190.HK stock price ended at $25.28 on 星期五, after dropping 1.33%
On the latest trading day Jan 16, 2026, the stock price of 02190.HK fell by 1.33%, dropping from $26.00 to $25.28. During the session, the stock saw a volatility of 7.32%, with prices oscillating between a daily low of $24.58 and a high of $26.38. On the latest trading day, the trading volume for 02190.HK decreased by 3.3K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 587.3K shares were traded, with a market value of approximately $8.1B.